Molecular docking simulations showed that the analogs can bind to the catalytic site of both aldose reductase and glucokinase in the treatment of T2DM, with emphasis on LASSBio-2129 due to its low affinity energy and high pharmacokinetic viability. The gene discussed is GCK; the disease is type 2 diabetes mellitus.